A patient suffering from acute myeloid leukemia (FAB M5a) received a PBSC allograft from a matched, related donor. On day 13 after transplantation severe hypophosphatemia (0.21 mmol/l) was first noted which persisted irrespective of intravenous phosphate administration, and within 2 days reached concentrations below 0.13 mmol/l. After repeated phosphate substitution serum phosphate returned to 1.40 mmol/l on day 17. Phosphate in urine, and calcium in serum were recorded as unchanged throughout. Clinical signs and symptoms due to severe hypophosphatemia were not observed except for paresthesia in the lower extremities. The precipitous fall in serum phosphate coincided with hematopoietic reconstitution as reflected by a steep rise in leukocyte count from 0.08 × 10 9
The reference range for inorganic serum phosphate is 0.80-1.30 mmol/l. Mild to moderate hypophosphatemia arbitrarily defined as 0.30-0.80 mmol/l is a frequently encountered laboratory finding in hospitalized patients, whereas severe hypophosphatemia quoted as a serum concentration below 0.30 mmol/l must be considered a rare but potentially life-threatening condition. 1 Severe hypophosphatemia leads to a wide range of clinical manifestations including cardiovascular, respiratory, neuromuscular, and hematological effects. Intravenous phosphate replacement may be required in these cases to correct the concentration of serum phosphate, thus ameliorating the risk of complications. 2 Although usually multifactorial in origin, the pathogenesis of hypophosphatemia includes the following mechanisms: inadequate phosphate intake, decreased intestinal absorption, gastrointestinal or renal phosphate loss, and redistribution of phosphate into cells. The latter mechanism might be the link between rapidly proliferating cells and severe hypophosphatemia as has been reported in patients suffering from hematological malignancies. 3, 4 Similarly, low serum phosphate concentrations have been reported in patients undergoing stem cell harvesting 5 or bone marrow/ peripheral blood stem cell transplantation.
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Case report
A 38-year-old male patient was diagnosed in December 1998 with acute myeloid leukemia FAB M5a. He was treated with courses of cytarabine, idarubicin/cytarabine, and mitoxantrone/cytarabine, and conditioning for stem cell transplantation including total body irradiation, VP16 and cyclophosphamide. 2.97 × 10 6 /kg body weight CD34 + peripheral blood stem cells from an HLA-identical related donor were given. Therapy-associated complications included mucositis (WHO grade IV), local skin toxicity after radiation (WHO grade II), hepatotoxicity and nephrotoxicity (WHO grade I), and infection (WHO grade IV). Engraftment was noted on day +14 (leukocyte count Ͼ1.0 × 10 9 /l), day +36 (platelet count Ͼ50 × 10 9 /l), and day +27 (hemoglobin Ͼ6.0 mmol/l), respectively.
Monitoring of serum electrolytes was unremarkable until day +13 when severe hypophosphatemia (0.21 mmol/l) was first observed. Despite initial intravenous phosphate substitution (30 mmol) the serum phosphate concentration decreased further and on day +15 reached levels below the limit of detection of the method employed (dry chemistry slide technology, Vitros 950; Johnson and Johnson, Rochester, NY, USA). The development of severe hypophosphatemia demonstrated an intriguing temporal relationship to hematopoietic recovery as reflected by the rapidly increasing leukocyte count from 0.08 × 10 9 /l on day +10 to 5.94 × 10 9 /l on day +15 (Figure 1 ). Other electrolyte abnormalities in serum and urine were not detected; specifically serum calcium concentrations were recorded as unchanged throughout. Intravenous phosphate substitution was repeated twice (30 mmol on day +15 and 50 mmol on day +16), and the serum phosphate returned to 1.40 mmol/l on day +17. Rebound hypocalcemic hyperphosphatemia did not occur. Paresthesia of the lower extremities resolved after correction of the serum phosphate. No other clinical signs and symptoms were observed which could unambiguously be associated with severe hypophosphatemia.
Discussion
Electrolyte and acid-base disturbances are common metabolic complications of malignant disorders. 8 In addition, hypophosphatemia of varying degrees has frequently been reported in association with sepsis and infection 9 and its timely recognition and treatment is of considerable importance in intensive care units. 10 In the absence of the recognized causes of hypophosphatemia including inadequate intake and loss of phosphate from the body, incorporation of inorganic phosphate by rapidly proliferating cells could significantly contribute to hypophosphatemia in hematological malignancies. 3 Resulting severe hypophosphatemia could, in turn, negatively affect the cellular formation of phosphate-containing compounds including adenosine triphosphate and 2,3-diphosphoglycerate necessary to maintain normal homeostasis. In agreement with several case reports, 5, 6, 11 the temporal relationship between decreasing inorganic phosphate in serum and rapidly increasing white blood cell count in our index patient adds further evidence to this hypothesis.
The incidence of hypophosphatemia in patients undergoing bone marrow/peripheral blood stem cell transplantation has not yet been systematically explored. In a retrospective study of bone marrow transplant recipients, Crook et al 7 reported that 77% (13 of 17) had a reduced serum phosphate at some stage in the conditioning phase or within 1 week thereafter. The same study identified two patients (11.8%) with severe hypophosphatemia (Ͻ0.30 mmol/l). Considering that hematopoietic recovery occurs later than day 7 after transplantation, the true incidence of hypophosphatemia is presumably even higher if assessed until complete hematopoietic reconstitution is achieved.
We recommend that serum electrolyte monitoring after bone marrow/peripheral blood stem cell transplantation should include daily analyses of inorganic phosphate. This approach will help clarify the frequency of severe hypophosphatemia, its metabolic and clinical effects, and phosphate replacement strategies for these patients can be devised.
